NHS approval for latest psoriasis biologic

NICE has recommended ixekizumab (Taltz) as an option for treating severe plaque psoriasis in adults who have responded inadequately to standard systemic therapies.

Ixekizumab is recommended as an option for treating severe plaque psoriasis that has responded inadequately to standard systemic therapies. | iStock
Ixekizumab is recommended as an option for treating severe plaque psoriasis that has responded inadequately to standard systemic therapies. | iStock

Ixekizumab is recommended as an option for treating severe plaque psoriasis, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10, when the disease has not responded to standard systemic therapies, or these treatments are contraindicated or the person cannot tolerate them.

As is the case for secukinumab (Cosentyx), NICE approval requires the company to provide the drug with the discount agreed in the patient access scheme.

NICE states that ixekizumab treatment should be stopped at 12 weeks if the psoriasis has not responded adequately (defined as a 75% reduction in the PASI score or a 50% reduction in the PASI score and a 5-point reduction in DLQI from baseline).

Earlier this month the Scottish Medicines Consortium accepted ixekizumab for use within NHS Scotland to treat moderate to severe plaque psoriasis in patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contraindication to these treatments.

Ixekizumab is licensed for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. It targets interleukin-17A, a cytokine that contributes to the pathogenesis of psoriasis by promoting keratinocyte proliferation and activation.

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

Oral psoriatic arthritis treatment accepted for NHS use

Oral psoriatic arthritis treatment accepted for NHS use

Apremilast (Otezla) has been approved by NICE for treating...

New immunomodulator for systemic treatment of psoriasis

New immunomodulator for systemic treatment of psoriasis

Ixekizumab is a monoclonal antibody that binds to and...

Secukinumab approved by NICE for severe psoriasis

Secukinumab approved by NICE for severe psoriasis

The monoclonal antibody secukinumab (Cosentyx) has...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases